Immunological fusion protein | InOncology – Boehringer Ingelheim

Immuno-modulators

*This is an investigational compound and has not been approved. Its safety and efficacy have not been established.

BI 3810944 is currently being investigated in a Phase I dose escalation and expansion trial in patients with solid tumors.¹

Immunological fusion protein (BI 3810944) clinical trial

NCT07224425
(1527-0001)¹

Trial design

Phase I Ph I Recruiting

Treatment:

BI 3810944 monotherapy

Patient population:

Solid tumors

Trial design

ClinicalTrials.gov. NCT07224425. https://clinicaltrials.gov/study/NCT07224425 (Accessed: April 2026).

You may also be interested in...

Go to page

A closeup of someone holding a medication sample that has rows of red, orange and yellow substances.

Oncology pipeline

Find out more about our preclinical and clinical investigational compounds.

R6 – Congress Hub

Congress publications

Explore the latest data that Boehringer Ingelheim has presented at recent congresses.

Go to page

tumor types in focus

Tumor types in focus

Get an overview of different cancer types and how recent advances may affect clinical decision making and treatment of these cancers.